Efficacy of probiotic Thai strains products in type 2 diabetes mellitus patients

Status

Unknown

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240917006

Enrollment

250

Registered

2024-09-17

Start date

2024-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

People with type 2 diabetes mellitus (T2DM) Probiotics, type 2 diabetes mellitus , food supplements, functional ingredients

Interventions

probiotic group 1:-L. reuteri TF314, B. animalis TA-1,L. reuteri TF-7, B. animalis MSMC83, L. paracasei MSMC39, L. reuteri TF314, B. animalis TA-1, L. paracasei MSMC39, L. reuteri TF-7, B. animalis MS

Experimental Dietary Supplement,Experimental Dietary Supplement,Experimental Dietary Supplement,Experimental Dietary Supplement,Placebo Comparator Dietary Supplement

probiotic group 1,probiotic group 2,probiotic group 3,probiotic group 4,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age 18 - 60 years Diagnosed with type 2 diabetes for 1 -15 years Taking metformin 500 mg fixed dose without adjusting the type and dose for more than 3 months Hemoglobin A1c between 7 - 9 % BMI between 23 t- 25 kg /m2

Exclusion criteria

Exclusion criteria: 1. Taking probiotics 2. Taking antibiotics 3. Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar 12 weeks Milligrams Per Deciliter ,hemoglobin A1c 12 weeks %	—

Secondary

Measure	Time frame
lipid profile 12 weeks Milligrams Per Deciliter ,gut microbiome 12 weeks Relative abundance	—

Countries

Thailand

Contacts

Public ContactMalai Taweechotipatr

Srinakharinwirot University

malai@g.swu.ac.th0860961314

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026